These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37995748)

  • 1. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials.
    Hsia J; Spyropoulos AC; Piazza G; Weng S; Dunne MW; Lipardi C; Barnathan ES; Bonaca MP
    Thromb Haemost; 2024 Jul; 124(7):649-655. PubMed ID: 37995748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
    Capell WH; Barnathan ES; Piazza G; Spyropoulos AC; Hsia J; Bull S; Lipardi C; Sugarmann C; Suh E; Rao JP; Hiatt WR; Bonaca MP
    Am Heart J; 2021 May; 235():12-23. PubMed ID: 33577800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
    Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP;
    Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials.
    Shen X; Qiu E; Liu Z; Zhu X; Zeng Y
    Saudi Med J; 2024 Apr; 45(4):341-348. PubMed ID: 38657982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
    J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
    N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
    Ramacciotti E; Agati LB; Calderaro D; Volpiani GG; de Oliveira CCC; Aguiar VCR; Rodrigues E; Sobreira ML; Joviliano EE; Dusilek C; Itinose K; Dedivitis RA; Cortina AS; Sanches SMV; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; Cavalcante BBM; Moreira RCR; Chiann C; Tafur A; Spyropoulos AC; Lopes RD
    Am Heart J; 2021 Dec; 242():115-122. PubMed ID: 34480880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
    Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
    JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
    Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
    J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
    Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
    Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).
    Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á
    Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
    Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani CP; O'Reilly EM; Patel JN; Yimer HA; Wildgoose P; Burton P; Vijapurkar U; Kaul S; Eikelboom J; McBane R; Bauer KA; Kuderer NM; Lyman GH;
    N Engl J Med; 2019 Feb; 380(8):720-728. PubMed ID: 30786186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
    Ambler GK; Nordanstig J; Behrendt CA; Twine CP
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
    [No Abstract]   [Full Text] [Related]  

  • 18. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
    Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
    Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.